ガドテル酸
WordNet
- street name for lysergic acid diethylamide (同)back breaker, battery-acid, dose, dot, Elvis, loony toons, Lucy in the sky with diamonds, pane, superman, window pane, Zen
- any of various water-soluble compounds having a sour taste and capable of turning litmus red and reacting with a base to form a salt
- having the characteristics of an acid; "an acid reaction"
PrepTutorEJDIC
- 酸性の / 酸味のある,すっぱい(sour) / (言葉・態度などが)厳しい,しんらつな / 酸 / すっぱいもの / 《俗》=LSD
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2017/10/11 18:25:40」(JST)
[Wiki en表示]
Gadoteric acid
|
| Clinical data |
| AHFS/Drugs.com |
International Drug Names |
| ATC code |
|
| Identifiers |
IUPAC name
- gadolinium(+3) cation; 2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate
|
| CAS Number |
|
| PubChem CID |
|
| UNII |
|
| KEGG |
|
| Chemical and physical data |
| Formula |
C16H25GdN4O8 |
| Molar mass |
558.64 g/mol |
| NY (what is this?) (verify) |
Gadoteric acid (gadoterate meglumine, trade names Artirem, Dotarem) is a macrocycle-structured gadolinium-based MRI contrast agent (GBCA). It consists of the organic acid DOTA as a chelating agent, and gadolinium (Gd3+), and is used in form of the meglumine salt (Gadoterate meglumine).[1]
It is used for imaging of blood vessels and inflamed or diseased tissue where the blood vessels become 'leaky'. It is often used when viewing intracranial lesions with abnormal vascularity or abnormalities in the blood–brain barrier. Gadoteric acid is used for MRI imaging of the brain, spine, and associated tissues for adult and pediatric (2 years of age or older) patients. The meglumine salt it takes the form of crosses the blood brain barrier of tissue with abnormal vasculature, highlighting the affected area with MRI. Gadoterate does not cross the intact blood-brain barrier, so it does not affect or enhance normal brain tissue in imaging.[2] Dotarem is administered through an intravenous bolus injection, either manually or through a power injection.[1]
The most common adverse effects (>0.2%) in clinical studies were nausea, headache, injection site pain, injection site coldness, and burning sensation. Drugs with gadolinium-based contrasting agents can increase the risk of nephrogenic systemic fibrosis (NSF) for those with impaired elimination of the drug. Those most at risk for NSF include patients with chronic or severe kidney disease and acute kidney injury.[1][3]
The paramagnetic property of gadoteric acid reduces the T1 relaxation time (and to some extent the T2 and T2* relaxation times) in MRI, which is the source of its clinical utility. Because it has magnetic properties, gadoteric acid develops a magnetic moment when put under a magnetic field, which increases the signal intensity (brightness) of tissues during MRI imaging.[2]
The drug, under the brand Dotarem, was brought to market by Guerbet.[4] As of 2013 gadoteric acid was approved in around 70 countries.[5][6] It was launched in the French market in 1989 and was FDA approved in the US in March, 2013.[4] Dotarem is the seventh FDA approved GBCA for use in central nervous system (CNS) MRI. In 2017, GE Healthcare launched a gadoteric acid (as gadoterate meglumine) under the trade name Clariscan[7] Other FDA approved GBCAs for similar purposes include Magnevist (1988), Prohance (1992), Omniscan (1993), Optimark (1999), Multihance (2004) and Gadavist (2011).[8]
References
- ^ a b c "US gadoterate meglumine label" (PDF). FDA. March 2013.
- ^ a b DrugBank, ed. (2016-08-22). "Gadoteric acid". DrugBank.
- ^ Todd, DJ; Kay, J (2016). "Gadolinium-Induced Fibrosis.". Annual Review of Medicine. 67: 273–91. PMID 26768242.
- ^ a b Hollmer, Mark (January 6, 2014). "Dotarem: A safe(r) gadolinium-based contrast imaging agent". FierceBiotech.
- ^ "Gadoteric Acid international brands". Drugs.com. Retrieved 7 March 2017.
- ^ Guerbet LLC (14 February 2013). "Advisory Committee Briefing Document for NDA 204-781". FDA.
- ^ http://www.mhra.gov.uk/home/groups/spcpil/documents/spcpil/con1487912585095.pdf
- ^ "Press Announcements - FDA approves Dotarem, a new magnetic resonance imaging agent". www.fda.gov. Retrieved 2016-11-14.
|
Contrast media (V08)
|
| X-ray and CT |
Iodinated,
Water soluble |
Nephrotropic,
high osmolar |
- Diatrizoic acid#
- Metrizoic acid
- Iodamide
- Iotalamic acid
- Ioxitalamic acid
- Ioglicic acid
- Acetrizoic acid
- Iocarmic acid
- Methiodal
- Diodone
|
Nephrotropic,
low osmolar |
- Metrizamide
- Iohexol#
- Ioxaglic acid
- Iopamidol
- Iopromide
- Iotrolan
- Ioversol
- Iopentol
- Iodixanol
- Iomeprol
- Iobitridol
- Ioxilan
|
| Hepatotropic |
- Iodoxamic acid
- Iotroxic acid
- Ioglycamic acid
- Adipiodone
- Iobenzamic acid
- Iopanoic acid
- Iocetamic acid
- Sodium iopodate
- Tyropanoic acid
- Calcium iopodate
|
|
Iodinated,
Water insoluble |
- Ethyl esters of iodised fatty acids
- Iopydol
- Propyliodone
- Iofendylate
- Lipiodol
|
| Non-iodinated |
|
|
| MRI |
| Paramagnetic |
- Gadolinium-based: Gadobenic acid
- Gadobutrol
- Gadodiamide
- Gadofosveset
- Gadolinium
- Gadopentetic acid
- Gadoteric acid
- Gadoteridol
- Gadoversetamide
- Gadoxetic acid
Other: Ferric ammonium citrate
|
| Superparamagnetic |
- Ferumoxsil
- Ferristene
- Iron oxide, nanoparticles
|
| Other |
|
|
| Ultrasound |
- Microspheres of human albumin
- Microparticles of galactose
- Perflenapent
- Microspheres of phospholipids
- Sulfur hexafluoride
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Absence of potential gadolinium toxicity symptoms following 22,897 gadoteric acid (Dotarem®) examinations, including 3,209 performed on renally insufficient individuals.
- Young LK, Matthew SZ, Houston JG.
- European radiology. 2019 Apr;29(4)1922-1930.
- Recent safety concerns regarding gadolinium-based contrast agents (GdCAs) concluded with the suspension of some agents from the European market, yet a clinical consequence remains unknown. We used electronic health records to investigate the incidence of potential toxicity to gadoteric acid (Dotarem
- PMID 30276674
- Treatment-related Focal Nodular Hyperplasia Mimicking Liver Metastases.
- Laino ME, Monti S, Klimstra DS, Tang LH, Mannelli L.
- Journal of pediatric hematology/oncology. 2019 Mar;41(2)138-139.
- A 7-year-old patient with a stage 4 neuroblastoma underwent chemotherapy, surgery, myeloablative therapy, external beam radiotherapy, and Isoretinoin treatment. A posttreatment magnetic resonance examination performed administering gadoteric acid as contrast agent showed 2 new hypervascular hepatic
- PMID 30499907
- Effects of Gadodiamide and Gadoteric Acid on Rat Kidneys: A Comparative Study.
- Celiker FB, Tumkaya L, Mercantepe T, Beyazal M, Turan A, Beyazal Polat H, Suzan ZT, Inecikli MF, Akyildiz K, Yilmaz A.
- Journal of magnetic resonance imaging : JMRI. 2019 Feb;49(2)382-389.
- Gadolinium-based contrast agents are complex chelates to provide contrast in NRI. However, recent studies have highlighted the deposition of free Gd ion in various tissues. To evaluate the histopathological and immunohistochemical changes on rat kidney tissue following both macrocyclic (gadoteric ac
- PMID 30209850
Related Links
- Gadoteric acid | C16H25GdN4O8 | CID 158536 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities ...
- Gadoteric acid is a macrocycle-structured gadolinium-based MRI contrast agent. It is composed of the organic acid DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) used for its chelating properties, and gadolinium ...
- Gadoteric acid, also known as gadoterate, belongs to the class of organic compounds known as tetracarboxylic acids and derivatives. These are carboxylic acids containing exactly four carboxyl groups. Gadoteric acid water